We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.72B
AUM Growth
-$442M
Cap. Flow
-$1.85B
Cap. Flow %
-67.9%
Top 10 Hldgs %
40.29%
Holding
91
New
5
Increased
13
Reduced
23
Closed
19

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$71.4M
2
PEN icon
Penumbra
PEN
+$28.2M
3
TRML
Tourmaline Bio
TRML
+$18.1M
4
GPCR icon
Structure Therapeutics
GPCR
+$16.1M
5
LNTH icon
Lantheus
LNTH
+$14M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$61.5M
2
NTRA icon
Natera
NTRA
+$44.8M
3
MRUS
Merus
MRUS
+$35.7M
4
ISRG icon
Intuitive Surgical
ISRG
+$33.6M
5
GKOS icon
Glaukos
GKOS
+$30.9M

Sector Composition

Rank Sector Weight
1 Miscellaneous 51.4%
2 Healthcare 48.6%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
26
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$18.9M 0.69%
1,169,490
-2,166,731
-65% -$27.6M
RGEN icon
27
Repligen
RGEN
$9.95B
$18.5M 0.68%
102,698
-15,702
-13% -$2.44M
MLYS icon
28
Mineralys Therapeutics
MLYS
$2.26B
$17.4M 0.64%
2,023,900
– –
HROW icon
29
Harrow
HROW
$1.4B
$16.8M 0.62%
1,498,584
-310,100
-17% -$3.67M
AMGN icon
30
Amgen
AMGN
$234B
$16.8M 0.62%
58,200
+22,000
+61% +$5.99M
TERN
31
DELISTED
Terns Pharmaceuticals
TERN
$15M 0.55%
2,318,050
-522,002
-18% -$2.76M
THRD
32
DELISTED
Third Harmonic Bio
THRD
$14.4M 0.53%
1,316,018
-337,973
-20% -$2.68M
OM icon
33
Outset Medical
OM
$74.1M
$13M 0.48%
160,028
– –
CGEM icon
34
Cullinan Oncology
CGEM
$1.4B
$12.6M 0.46%
1,240,865
-668,000
-35% -$5.92M
GPCR icon
35
Structure Therapeutics
GPCR
$3.38B
$11.4M 0.42%
+280,158
New +$16.1M
SYRE icon
36
Spyre Therapeutics
SYRE
$7.97B
$11.1M 0.41%
+515,000
New +$7.09M
MRUS
37
DELISTED
Merus
MRUS
$10.2M 0.37%
370,679
-1,530,658
-81% -$35.7M
DYN icon
38
Dyne Therapeutics
DYN
$4.68B
$10.1M 0.37%
755,811
-1,066,161
-59% -$10.4M
LUNG icon
39
Pulmonx
LUNG
$102M
$10M 0.37%
787,954
-200,605
-20% -$2.09M
DNLI icon
40
Denali Therapeutics
DNLI
$3.84B
$9.91M 0.36%
+461,769
New +$9.15M
RAPT
41
DELISTED
RAPT Therapeutics
RAPT
$9.67M 0.36%
48,663
-86,651
-64% -$10.7M
TMDX icon
42
Transmedics
TMDX
$3.07B
$9.29M 0.34%
117,701
-189,499
-62% -$11.4M
DBVT
43
DBV Technologies
DBVT
$851M
$7.47M 0.27%
784,329
-426,450
-35% -$4.13M
VRDN icon
44
Viridian Therapeutics
VRDN
$2.61B
$7.04M 0.26%
323,102
-1,412,080
-81% -$22.3M
ADPT icon
45
Adaptive Biotechnologies
ADPT
$4.02B
$6.65M 0.24%
1,357,490
+389,800
+40% +$1.78M
HLVX
46
DELISTED
HilleVax
HLVX
$3.26M 0.12%
203,407
-1,245,839
-86% -$16.6M
CMPX icon
47
Compass Therapeutics
CMPX
$432M
$496K 0.02%
317,761
-5,636,512
-95% -$9.75M
AGEN
48
Agenus
AGEN
$345M
– –
-315,352
Closed -$7.13M
ALXO icon
49
ALX Oncology
ALXO
$277M
– –
-1,249,900
Closed -$6M
ANAB icon
50
AnaptysBio
ANAB
$1.67B
– –
-1,049,823
Closed -$18.9M
1
2
3

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q4 2023 Portfolio in Review

As of Q4 2023, Braidwell held 91 positions worth $2.72B, down 14% from $3.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Braidwell withdrew a net $1.85B in Q4 2023, closing 19 positions and reducing 23 holdings. Its most notable exit was Boston Scientific, an estimated $61.5M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 51% of assets, up from 48% a quarter earlier, followed by Healthcare and Consumer Staples.

Against the trend, Braidwell opened a new position in argenx worth $58.3M.

  • Braidwell's largest Q4 2023 buy was argenx: 153,204 shares worth $58.3M.
  • Braidwell added most to Penumbra in Q4 2023, an estimated $28.2M increase.
  • Braidwell's biggest Q4 2023 reduction was Merus, cutting an estimated $35.7M.
  • Braidwell fully exited Boston Scientific in Q4 2023, selling an estimated $61.5M.
  • Braidwell's ten largest holdings make up 40% of its $2.72B portfolio in Q4 2023.
  • Braidwell opened 5 new positions and closed 19 in Q4 2023.
  • Braidwell's portfolio value fell 14% quarter-over-quarter to $2.72B.

Based on Braidwell's 13F filing for Q4 2023, filed 14 Feb 2024.